CN109562065A - 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法 - Google Patents

靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法 Download PDF

Info

Publication number
CN109562065A
CN109562065A CN201780047015.5A CN201780047015A CN109562065A CN 109562065 A CN109562065 A CN 109562065A CN 201780047015 A CN201780047015 A CN 201780047015A CN 109562065 A CN109562065 A CN 109562065A
Authority
CN
China
Prior art keywords
sbt
dha
cancer
pufa
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780047015.5A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·E·伊根
伊瓦奥·奥吉马
曼苏尔·M·阿米吉
加林娜·伊凡诺夫娜·伯奇基娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targagenix Inc
Research Foundation of the State University of New York
Original Assignee
Targagenix Inc
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targagenix Inc, Research Foundation of the State University of New York filed Critical Targagenix Inc
Priority to CN202310169465.9A priority Critical patent/CN116019768A/zh
Publication of CN109562065A publication Critical patent/CN109562065A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780047015.5A 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法 Pending CN109562065A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310169465.9A CN116019768A (zh) 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346755P 2016-06-07 2016-06-07
US62/346,755 2016-06-07
PCT/US2017/036330 WO2017214260A1 (en) 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310169465.9A Division CN116019768A (zh) 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN109562065A true CN109562065A (zh) 2019-04-02

Family

ID=60578981

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780047015.5A Pending CN109562065A (zh) 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
CN202310169465.9A Pending CN116019768A (zh) 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310169465.9A Pending CN116019768A (zh) 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法

Country Status (9)

Country Link
US (3) US10206875B2 (enExample)
EP (1) EP3463299A4 (enExample)
JP (1) JP7518604B2 (enExample)
CN (2) CN109562065A (enExample)
AU (1) AU2017277497B2 (enExample)
CA (1) CA3026412A1 (enExample)
IL (1) IL263504A (enExample)
MX (1) MX2018015112A (enExample)
WO (1) WO2017214260A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114599394A (zh) * 2019-10-25 2022-06-07 安进公司 用于在低蛋白浓度下使蛋白损失最小化的组合物和方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562065A (zh) * 2016-06-07 2019-04-02 塔佳吉尼克斯公司 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
US11497713B2 (en) * 2017-12-20 2022-11-15 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer
KR20210142152A (ko) * 2019-03-22 2021-11-24 인티그레이티드 나노테라퓨틱스 아이엔씨. 스캐폴드 모이어티로부터 제조된 지질 접합체
WO2021092225A2 (en) * 2019-11-05 2021-05-14 Luminus Biosciences, Inc. Nanoparticles comprising prodrugs stabilized by albumin for treatment of cancer and other diseases
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114317398B (zh) * 2020-09-27 2024-03-01 中国科学院分子细胞科学卓越创新中心 Gli1和EpCAM基因共同标记的肝祖细胞群及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1901901A (zh) * 2003-10-30 2007-01-24 纽约州州立大学研究基金会 紫杉醇－脂肪酸结合物及其药物组合物
CN101094646A (zh) * 2004-09-28 2007-12-26 陈献 用于输送紫杉烷及其它不溶性药物的低油乳剂组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
WO2010018596A2 (en) * 2008-07-23 2010-02-18 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water docetaxel nanoemulsion
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
US20140105829A1 (en) * 2012-10-15 2014-04-17 Nemucore Medical Innovations, Inc. Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same
DK3157508T3 (da) * 2014-06-19 2021-02-15 Solural Pharma ApS Fast oral doseringsform af lipofile forbindelser
WO2015198350A1 (en) * 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
CN109562065A (zh) * 2016-06-07 2019-04-02 塔佳吉尼克斯公司 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
US11497713B2 (en) * 2017-12-20 2022-11-15 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1901901A (zh) * 2003-10-30 2007-01-24 纽约州州立大学研究基金会 紫杉醇－脂肪酸结合物及其药物组合物
CN101094646A (zh) * 2004-09-28 2007-12-26 陈献 用于输送紫杉烷及其它不溶性药物的低油乳剂组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陆彬: "《《药物新剂型与新技术》》", 31 July 2005, 人民卫生出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114599394A (zh) * 2019-10-25 2022-06-07 安进公司 用于在低蛋白浓度下使蛋白损失最小化的组合物和方法

Also Published As

Publication number Publication date
MX2018015112A (es) 2019-09-09
EP3463299A4 (en) 2020-01-15
CA3026412A1 (en) 2017-12-14
US20180028442A1 (en) 2018-02-01
CN116019768A (zh) 2023-04-28
IL263504A (en) 2019-01-31
JP7518604B2 (ja) 2024-07-18
US20250009658A1 (en) 2025-01-09
AU2017277497A1 (en) 2018-12-20
NZ748915A (en) 2024-09-27
JP2019523226A (ja) 2019-08-22
WO2017214260A1 (en) 2017-12-14
EP3463299A1 (en) 2019-04-10
USRE50096E1 (en) 2024-08-27
AU2017277497B2 (en) 2023-05-04
US10206875B2 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
CN109562065A (zh) 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
Liu et al. Focused ultrasound-augmented targeting delivery of nanosonosensitizers from homogenous exosomes for enhanced sonodynamic cancer therapy
Ahmad et al. Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth
Han et al. A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer
Ravar et al. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation
Naguib et al. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation
Chiang et al. Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds
Tummala et al. Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles
Sabzichi et al. Fabrication of all-trans-retinoic acid-loaded biocompatible precirol: A strategy for escaping dose-dependent side effects of doxorubicin
Gülçür et al. Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells
Pan et al. Recent advances in boosting EGFR tyrosine kinase inhibitors-based cancer therapy
Rahman et al. Nanomedicine-based drug-targeting in breast cancer: pharmacokinetics, clinical progress, and challenges
Guo et al. Transferrin-functionalized microemulsions coloaded with coix seed oil and tripterine deeply penetrate to improve cervical cancer therapy
Raikwar et al. Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape
Kim et al. Enhanced docetaxel delivery using sterically stabilized RIPL peptide-conjugated nanostructured lipid carriers: In vitro and in vivo antitumor efficacy against SKOV3 ovarian cancer cells
US12186428B2 (en) Combination taxoid nanoemulsion with immunotherapy in cancer
Singh et al. Reprogramming cancer stem-like cells with nanoforskolin enhances the efficacy of paclitaxel in targeting breast cancer
Wang et al. Efficient tumor-targeting delivery of siRNA via folate-receptor mediated biomimetic albumin nanoparticles enhanced by all-trans retinoic acid
Bteich et al. Nanoparticle formulation derived from carboxymethyl cellulose, polyethylene glycol, and cabazitaxel for chemotherapy delivery to the brain
Rajendra et al. Fabrication and in vitro evaluation of silk fibroin-folic acid decorated paclitaxel and hydroxyurea nanostructured lipid carriers for targeting ovarian cancer cells: A double sword approach
Qu et al. Fever-inducible lipid nanocomposite for boosting cancer therapy through synergistic engineering of a tumor microenvironment
Bahreyni et al. Engineering a facile and versatile nanoplatform to facilitate the delivery of multiple agents for targeted breast cancer chemo-immunotherapy
Ren et al. A carrier-free ultrasound-responsive polyphenol nanonetworks with enhanced sonodynamic-immunotherapy for synergistic therapy of breast cancer
Tang et al. Glycyrrhetinic acid remodels the tumor microenvironment and synergizes with doxorubicin for breast cancer treatment in a murine model
Kong et al. Targeted codelivery of doxorubicin and oleanolic acid by reduction responsive hyaluronic acid-based prodrug nano-micelles for enhanced antitumor activity and reduced toxicity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190402